Your session is about to expire
← Back to Search
Bexmarilimab for Cancer (MATINS Trial)
MATINS Trial Summary
This trial is testing whether a new drug, FP-1305, is suitable for use in humans. The drug is being tested on patients with advanced cancer who have exhausted all other treatment options. The drug works by binding to a receptor called CLEVER-1, which is known to support tumor growth. Previous studies in animals have shown that FP-1305 is safe and effective, and the dose being used in this trial is 300 times lower than the dose that was safe in animals.
MATINS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMATINS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MATINS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had an organ transplant.You have received any immunotherapy treatment in the last 6 weeks before starting the study.You are currently taking medications that weaken your immune system, like corticosteroids or other immunosuppressive drugs.You are expected to live for at least 12 more weeks.You have been diagnosed with gallbladder cancer or a specific type of liver cancer called cholangiocarcinoma.You have a medical condition that may put your safety at risk during the study, or make it difficult to understand the results of the treatment.You have advanced cancer that cannot be treated with standard therapies.
- Group 1: FP-1305 (bexmarilimab) 0.3 mg/kg
- Group 2: FP-1305 (bexmarilimab) 1 mg/kg
- Group 3: FP-1305 (bexmarilimab) 3 mg/kg
- Group 4: FP-1305 (bexmarilimab) 10 mg/kg
- Group 5: FP-1305 (bexmarilimab) 0.1 mg/kg
- Group 6: FP-1305 (bexmarilimab) 30 mg/kg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To the best of your knowledge, has this type of clinical trial been conducted before?
"The development of FP-1305 began in 2018 with a study that was funded by Faron Pharmaceuticals Ltd. Since then, the medication has undergone Phase 1 & 2 clinical trials and 700 patients have been involved in total. Now, there are 2 ongoing trials in 2 cities and 6 nations."
How many people can still join this trial?
"This investigation, which was originally advertised on December 3rd, 2018, is still looking for participants according to the clinicaltrials.gov website."
To what extent has FP-1305 been researched in the past?
"At present time, there are 2 ongoing clinical trials investigating FP-1305 with 0 trials in Phase 3. While many of the clinical trials for FP-1305 are based in Oulu, Texas, there are 12 locations worldwide operating clinical trials for FP-1305."
Share this study with friends
Copy Link
Messenger